Samrat Pharmachem Reports FY26 Net Loss Amidst Rising Costs

Samrat Pharmachem Limited has announced a net loss of ₹3.31 crore for the financial year ended March 31, 2026. This marks a significant downturn from the net profit of ₹7.11 crore recorded in the previous fiscal year, FY25.

Reader Takeaway: Net loss driven by cost pressures contrasts with improved operational cash flow and clean audit.

What just happened

Samrat Pharmachem reported a net loss of ₹3.31 crore for FY26. This is a reversal from a net profit of ₹7.11 crore in FY25. Revenue from operations saw a marginal increase to ₹289.72 crore from ₹285.86 crore in the prior year. However, expenses, particularly the Cost of Material Consumed, rose substantially, leading to the overall loss.

Why this matters

The shift to a loss-making position is a key concern for investors. It indicates that the company could not effectively manage rising input costs, impacting its bottom line. While the auditor provided an unmodified opinion, suggesting financial statement reliability, the profitability decline requires attention.

The backstory

In FY25, Samrat Pharmachem had reported a net profit of ₹7.11 crore and basic Earnings Per Share (EPS) of ₹23.02. The company's revenue was ₹285.86 crore. The previous year's performance showed a healthier financial position before the cost pressures of FY26.

What changes now

Investors will need to monitor how Samrat Pharmachem addresses its cost of material consumption. The company's ability to negotiate better raw material prices, improve operational efficiencies, or pass on costs to customers will be crucial for future profitability. The upcoming Annual General Meeting (AGM) on September 23, 2026, will be a forum for discussing these challenges.

Risks to watch

The primary risk is the continued escalation of material costs, which directly erodes margins. If the company cannot control these costs or pass them on, it may face further financial strain. The net loss in FY26 highlights this vulnerability.

Context metrics

• Revenue from Operations: ₹289.72 crore in FY26, up 1.35% from ₹285.86 crore in FY25.
• Cost of Material Consumed: ₹289.67 crore in FY26, up from ₹269.27 crore in FY25.
• Net Profit/(Loss): ₹(3.31) crore in FY26, compared to ₹7.11 crore in FY25.
• Net cash from operations: ₹8.88 crore in FY26, improved from ₹(10.09) crore in FY25.

What to track next

Investors should closely watch the company's future quarterly results to see if the trend of rising material costs continues and how the company's management plans to mitigate this. Any strategic changes in procurement or pricing will be key indicators.